Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ophthalmology
Biotech
Opthea scraps wet AMD program after eye drug loses to Lucentis
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet AMD program.
James Waldron
Mar 31, 2025 6:55am
Alcon gains majority stake in Aurion after power struggle
Mar 27, 2025 9:23am
Surrozen drops sole clinical-stage drug over weak hepatitis data
Mar 24, 2025 10:50am
Opthea's eye disease drug defeated by Eylea in phase 3
Mar 24, 2025 5:24am
Qlaris sees double as drug reduces eye pressure in ph. 2 trials
Feb 5, 2025 9:53am
Aviceda raises $207M for geographic atrophy drug's ph. 3 journey
Jan 7, 2025 9:38am
